<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>30(12)</volume><submitter>Tews HC</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Accurate biomarkers for disease activity and progression in patients with inflammatory bowel disease (IBD) are a prerequisite for individual disease characterization and personalized therapy. We show that metabolic profiling of serum from IBD patients is a promising approach to establish biomarkers. The aim of this work was to characterize metabolomic and lipidomic serum profiles of IBD patients in order to identify metabolic fingerprints unique to the disease.&lt;h4>Methods&lt;/h4>Serum samples were obtained from 55 patients with Crohn's disease (CD), 34 patients with ulcerative colitis (UC), and 40 healthy control (HC) individuals and analyzed using proton nuclear magnetic resonance spectroscopy. Classification of patients and HC individuals was achieved by orthogonal partia</pubmed_abstract><journal>Inflammatory bowel diseases</journal><pagination>2405-2417</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11630276</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Unique Metabolomic and Lipidomic Profile in Serum From Patients With Crohn's Disease and Ulcerative Colitis Compared With Healthy Control Individuals.</pubmed_title><pmcid>PMC11630276</pmcid><pubmed_authors>Gunther UL</pubmed_authors><pubmed_authors>Muller M</pubmed_authors><pubmed_authors>Loibl J</pubmed_authors><pubmed_authors>Gunawan S</pubmed_authors><pubmed_authors>Derer S</pubmed_authors><pubmed_authors>Schmelter F</pubmed_authors><pubmed_authors>Tews HC</pubmed_authors><pubmed_authors>Marquardt JU</pubmed_authors><pubmed_authors>Foh B</pubmed_authors><pubmed_authors>Schmid S</pubmed_authors><pubmed_authors>Sommersberger S</pubmed_authors><pubmed_authors>Sina C</pubmed_authors><pubmed_authors>Kandulski A</pubmed_authors><pubmed_authors>Buchler C</pubmed_authors><pubmed_authors>Elger T</pubmed_authors><pubmed_authors>Bettenworth D</pubmed_authors><pubmed_authors>Schlosser S</pubmed_authors><pubmed_authors>Kunst C</pubmed_authors><pubmed_authors>Gulow K</pubmed_authors><pubmed_authors>Solbach P</pubmed_authors><pubmed_authors>Fererberger T</pubmed_authors><pubmed_authors>Maaß C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Unique Metabolomic and Lipidomic Profile in Serum From Patients With Crohn's Disease and Ulcerative Colitis Compared With Healthy Control Individuals.</name><description>&lt;h4>Background&lt;/h4>Accurate biomarkers for disease activity and progression in patients with inflammatory bowel disease (IBD) are a prerequisite for individual disease characterization and personalized therapy. We show that metabolic profiling of serum from IBD patients is a promising approach to establish biomarkers. The aim of this work was to characterize metabolomic and lipidomic serum profiles of IBD patients in order to identify metabolic fingerprints unique to the disease.&lt;h4>Methods&lt;/h4>Serum samples were obtained from 55 patients with Crohn's disease (CD), 34 patients with ulcerative colitis (UC), and 40 healthy control (HC) individuals and analyzed using proton nuclear magnetic resonance spectroscopy. Classification of patients and HC individuals was achieved by orthogonal partia</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Dec</publication><modification>2025-04-26T23:21:38.142Z</modification><creation>2025-04-06T17:30:32.157Z</creation></dates><accession>S-EPMC11630276</accession><cross_references><pubmed>38156773</pubmed><doi>10.1093/ibd/izad298</doi></cross_references></HashMap>